Twelve-months treatment with dapagliflozin improves endothelial glycocalyx and cardiovascular function in patients with type 1 diabetes mellitus

1 September 2024 (16:00 - 16:40)
Organised by: Logo
Congress Presentation Part of: Diabetes and heart disease Metabolic Syndrome, Insulin, Insulin Resistance ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

ESC 365 is supported by

ESC 365 is supported by